UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2020

BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38659**	**26-4333375**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

54 Wilton Road, 2nd Floor **Westport, Connecticut**	**06880**
(Address of principal executive offices)	(Zip Code)

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 27, 2020, Ken Londoner of BioSig Technologies, Inc. (the "Company") will present a slide presentation, attached hereto as Exhibit 99.1, at LD Micro's Zooming with LD. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 8.01 Other Events

On July 23, 2020, the Company issued a press release announcing that it will be presenting at LD Micro's Zooming with LD on July 27, 2020. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	LD Micro Presentation - July 27, 2020 (furnished herewith pursuant to Item 7.01)
99.2	Press Release, dated July 23, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 27, 2020

By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman

Exhibit 99.1


BioSig technologies
BioSig Technologies
Ken Londoner, Founder, Chairman and CEO
Zooming with LD
July 27th, 2020
NASDAQ : BSGM
BioSig technologies
SYMBOL: BSGM
1

Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

BioSig Technologies Positioned for Success

- **Multi-billion dollar electrophysiology (EP) market**
  - Demand driven by high prevalence of arrhythmia
  - Procedures more efficacious than drugs, predicated on ability to analyze clean cardiac signals
- **Differentiated value proposition and impact to the patient**
  - Current standard of care negatively affected by signal "noise" and artifacts
  - PURE EP™ System offers a cleaner signal and potentially superior patient outcomes
- **ViralClear subsidiary testing an anti-viral therapy for COVID-19**
  - Broad-spectrum anti-viral now in Phase II clinical trial in Texas and Mayo Clinic sites
  - In vitro studies shown 98% reduction in viral load
- **Robust commercialization strategy – FDA cleared technology**
  - Supported by world-renowned key opinion leaders
  - Strategy led by a dynamic, experienced team
- **Strong intellectual property portfolio**
  - 26 allowed / issued worldwide design and utility patents

Strong Performance by both MedTech and Pharmaceutical Divisions

First-class industry experience

- Growing team of experienced clinical and commercial specialists
- Conducting *daily* patient cases with PURE EP™ at two high-volume centers; new installations in Q3
- Enrolling patients into Phase II clinical trial for COVID-19 in some of the most impacted states – *data expected in Q3*
- Robust US-based supply chain

Growing industry presence

- Presenting at 5 conferences in 2020
- Formally invited to showcase PURE EP™ during live cases at Texas Cardiac Arrhythmia Institute in Q4
- 3 clinical data abstracts accepted for publication in 2020

Robust financial performance

- Stock up 34% year-to-date
- Significantly outperformed Dow and Russell 2000
- Raised $38.3 million in 2020
- Strong capital markets and capital architecture expertise

BioSig technologies

PURE EP™ at-a-glance

- **FDA cleared device:** non-invasive platform technology provides detailed intracardiac information
- **Innovative system architecture:** acquisition of high-fidelity cardiac analog signals in an original unfiltered format
- **Unique value proposition:** demonstrated ability to maintain signal integrity even in the most complex arrhythmias
- **Seamless integration:** compatible with EP recording and 3D mapping systems without workflow disruptions
- **Modular design:** pipeline of software modules as additional revenue drivers

PURE EP™ Developed Through Collaboration with Leading Centers

Relationships at leading, high-volume centers create traction for PURE EP™ in the market



Driving Market Awareness Through Physician Insights

APR 2020: EP Lab Digest

Interview with Andrea Natale, M.D. – Texas Cardiac Arrhythmia Institute (TCAI)

BioSig technologies



MAY 2020: Stanford Arrhythmia Symposium

Presentation by Mayo Clinic on shortcomings in EP and how PURE EP™ is addressing them

(audience of ca. 320 physicians)

AF SYMPOSIUM

Spotlight Session

PURE EP™ - Technology Experience

Andrea Natale, MD, TCAI

(audience of ca. 250 physicians)

JUN - JUL 2020- HRS SCIENCE 2020

Educational talks by Mayo Clinic on novel signal acquisition systems

(audience of ca. 400 physicians)

Case Reviews *(5min videos)*

The impact of PURE EP™ during EP procedures

Defining the Market Opportunity

Global Growth in EP Devices:

$4.5B in 2017, projected to reach **$7.4B in 2022**

10.4% growth rate

Global Growth
in Complex Cardiac Ablation Procedures:

440,629 in 2017 to **830,390 in 2022**

13.5% growth rate



U.S.
1,631 hospitals averaging 2.1 rooms per lab

3,425

EP rooms

OUS:
3,729 hospitals averaging 1.05 rooms per lab

3,915

EP rooms

Data source: 2018 MD&D report

As Hospitals Resume Elective Procedures, Should they Prioritize Electrophysiology During COVID-19?

EP procedures are clinically urgent

Delaying procedure increases stroke risk and worsens outcomes

EP procedures are revenue generating

CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines

Median Revenues Per Case For Ablation and Select EP Procedures



Data Source: Advisory Board, Published by Cardiovascular Rounds

Reimbursement rates continue to increase

CMS Reimbursement Changes From FY 2019 to FY 2020

Procedure	Reimbursement Rate Change
Inpatient	
All inpatient services	2.5%
Ablations and LAAO (DRG 274	**8.8%**
Pacemaker implant (DRG 244)	0.9%
ICD implant (DRG 227)	0.9%
Outpatient	
All outpatient services	2.6%
Ablations (APC 5213)	6.3%
Pacemaker implant (APC 5223	3.8%
ICD implant (APC 5232)	5.3%

COVID-19 Asset Developed by Subsidiary, ViralClear Pharmaceuticals

- **Merimepodib, lead compound, currently in Phase II clinical trial for COVID-19**
  - Broad-spectrum, orally administered anti-viral previously tested in other indications
  - Commenced Phase II clinical trial in June 2020 at Mayo Clinic under the leadership of Andrew D. Badley, M.D., Enterprise Chair of the COVID-19 Task Force
  - Studies include in-hospital combination therapy with remdesivir
  - Extensive development work completed to shorten time to market
  - Subsidiary raised $10.8 million in May 2020
  - **Top line data expected in Q3 2020**
- **Exceptionally strong, expert management team**
  - Dr. Jerome B. Zeldis (CMO) - former Chief Medical Officer of Celgene
  - Steve King (COO) - extensive small molecule outsourcing drug development expertise from development through to commercial launch
- **Strong scientific rationale and data support treatment for COVID-19**
  - Immune modulation, tested at Galveston National Laboratory at UTMB
  - *In vitro* studies shown 98% reduction in viral load
  - First *in vitro* data published in online peer-reviewed journal
- **Clean safety profile**
  - 437 patients previously treated in other indications
  - Anticipated length of treatment is 14 days or less

ViralClear

BioSig technologies

Unique Collaboration with Mayo Clinic

- 10-year strategic agreement
  - Collaboration on technology development
  - Joint IP filings
  - Licensing opportunities
  - Mayo Clinic has invested capital in the development of the PURE EP™ System
- Phase II clinical trial support for ViralClear Pharmaceuticals, Inc.
- First PURE EP™ System installed at Mayo Clinic in Florida in January 2020

Key Milestones

2020

- ✓ Targeted commercial release of PURE EP™ System
- ✓ Obtain top line Phase II clinical data for merimepodib
- ✓ Initiate Phase III pivotal trial for COVID-19
- ✓ Develop new product pipeline to complement PURE EP™
- ✓ File further IP

2021

- ✓ Accelerate commercialization of PURE EP™ in U.S.
- ✓ Deliver Phase III results for COVID-19 therapy
- ✓ File further IP, advance R&D in bioelectronic medicine
- ✓ Clinical data publication and new evidence-based trials
- ✓ Gain European regulatory approval for PURE EP™
- ✓ Explore strategic partnerships and licensing opportunities

TEXAS CARDIAC ARRHYTHMIA | MAYO CLINIC | Penn | MGH MASSACHUSETTS GENERAL HOSPITAL

Seasoned Management Team, Possessing the Necessary Skillset and Knowledge to Drive Commercialization

Kenneth L. Londoner, MBA
Founder, Chairman, CEO, Director
NeuroClear Technologies; ViralClear Pharmaceuticals; Endicott Management Partners; J &W Seligman & Co.

Steve Chaussy, CPA
CFO
NeuroClear Technologies; Liberski Inc; Anna & Co; Penske Automotive; Ford Hogg and Cobbe

Natasha Drapeau
Executive Vice President
NeuroClear Technologies; Alliance for Advancing Bioelectronic Medicine; Institute of Directors, UK; IG Group Plc, UK

Andy Ballou
Vice President, Investor Relations
Janney Montgomery Scott; RBC Capital Markets

Barry Keenan, Ph.D, MBA, PMP
Vice President, Engineering
Medtronic; Nexeon MedSystems; Alfred Mann Institute for Biomedical Engineering; Alfred Mann Foundation for Scientific Research

John Kowalski
Vice President, Sales
Biosense Webster (Johnson & Johnson)

Julie Stephenson, BSN, MBA
Vice President, Clinical Affairs
Medtronic; Boston Scientific; Guidant Corporation

Manasi Patwardhan
Director of Strategic Planning Verily Life Sciences, Boston Scientific - Neuromodulation; Medtronic

Olivier Chaudoir
Senior Director, Marketing
Biosense Webster; DePuy Synthes

Business Model Summary

Highlights:

- PURE EP™ System expected to generate revenue beginning in H2 2020
- Decreasing annual cash burn in 2020
- Scaling up organization through increasing salesforce and extending relationships with world-class healthcare institutions
- Robust commercial strategy led by highly experienced team
- Strong product pipeline to capitalize on the already validated core competencies of PURE EP™ System
- Additional product pipeline covering novel therapies for autonomic nervous system disease
- Strategic partnerships with leading centers
- In March 2020, acquires the license for merimepodib, a broad-spectrum anti-viral to treat COVID-19. Currently in Phase II clinical trial across multiple sites.

BSGM Snapshot:

Key Company Data	(07/22/20)
Recent price:	$7.94
52-week range:	$2.36 - $12.43
Primary shares i/o:	28.4 million
Public float:	21.9 million
Market cap:	$230.97 million
Average volume (1 month):	1,071,596 shares

Exhibit 99.2

BioSig Technologies to Participate in LD Micro's Zooming with LD

Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig's pharmaceutical subsidiary and conduct virtual one-on-one meetings with investors

Westport, CT, July 23, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced today that the Company would be presenting at LD Micro's *Zooming with LD* on Monday, July 27, 2020.

Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting an overview of the Company as well as recent developments and key highlights, including progress with PURE EP(tm) system installations, the implementation of a stockholders rights plan, BioSig's subsidiary ViralClear Pharmaceuticals, Inc.'s (ViralClear) creation of a Scientific Advisory Board and enrollment of its Phase II clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19.

"With our stock up 34% year-to-date and the strongest balance sheet in the Company's history, we are well-positioned for continuous value creation on behalf of our shareholders. Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) System's ongoing and future installations. Our pharmaceutical subsidiary ViralClear sees a steady patient enrollment across many hospital sites. We are pleased to reconnect with the LD Micro investor community and look forward to reporting on our progress," commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

The BioSig presentation will take place virtually over Zoom on Monday, July 27th. Mr. Londoner will also be available for one-on-one meetings with investors on the same day.

To register for this 8 am PST presentation, click here.

About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America with market capitalizations between $50 million to $300 million.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company's first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD)
BioSig Technologies, Inc.'s (BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed. A manuscript titled, "The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro", was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. ("ViralClear") as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133